Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIAD: N0892 Triple Combination in Type 2 Diabetes
NCT06560333Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Nov 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin + sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Eurofarma. Planned start Nov 2026; status: withdrawn.
02
Drugs
dapagliflozin + sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06560333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560333.